MJMD: Good that Lusk is cancelling the 5mil share purchase from Caduceus Ltd. That purchase was an issue cited in my 05/04 review here. OTCM shows 63m as of January 2014. Updating the OTCM profile page to reflect the reported 89m O/S would signal adherence to openness. If Lusk progresses along the straight and narrow path and deals square with shareholders and public, his firm will be rewarded. A reputable OTC mmj with good prospects will stand out like a small gold nugget in a muddy stream.